Cardiac Success
Cardiac Success pioneers innovative transcatheter procedures to treat heart failure patients by directly reshaping the ventricle, halting deterioration, reducing symptoms, and initiating heart recovery. Their approach focuses on therapeutic remodeling of the heart, especially for patients with reduced ejection fraction, aiming to reverse the vicious cycle of pathological heart remodeling.
Industries
Nr. of Employees
small (1-50)
Cardiac Success
Ofer Bldg. 2, Yokneam High Tech Park, 2069202 P.O. Box 128, Israel
Patents
Products
Investigational transcatheter ventricular repair implant
An investigational, atraumatic, size-adjustable implant delivered via a low-profile transcatheter delivery system to reshape the dilated left ventricle for patients with reduced ejection fraction.
Investigational transcatheter ventricular repair implant
An investigational, atraumatic, size-adjustable implant delivered via a low-profile transcatheter delivery system to reshape the dilated left ventricle for patients with reduced ejection fraction.
Services
Design and execution of focused clinical studies for investigational cardiac implants, including patient selection, site-based follow-up and outcome reporting.
Design and execution of focused clinical studies for investigational cardiac implants, including patient selection, site-based follow-up and outcome reporting.
Expertise Areas
- Transcatheter structural heart device development
- Ventricular remodeling therapy for HFrEF
- Clinical trial management for investigational cardiac devices
- Regulatory strategy and submissions for medical devices
Key Technologies
- Transcatheter ventricular repair
- Ventricular remodeling therapy
- Low-profile catheter delivery systems
- Implantable cardiac sling/implant design
News & Updates
The Vsling technology was highlighted as a pioneering solution in the heart failure arena, with presentations by esteemed speakers including Dr. Gregg W. Stone, Dr. Horst Sievert, and CEO Mr. Boaz Manash.
Funds to accelerate the clinical development of the V-sling system, a transcatheter ventricular repair implant for heart failure patients.
The round was led by 415 CAPITAL, a venture capital firm specializing in medical technology, with additional strategic investors.
Awarded €10M in grants and equity investment to accelerate clinical development of the V-sling system.
The Vsling technology was highlighted as a pioneering solution in the heart failure arena, with presentations by esteemed speakers including Dr. Gregg W. Stone, Dr. Horst Sievert, and CEO Mr. Boaz Manash.
Funds to accelerate the clinical development of the V-sling system, a transcatheter ventricular repair implant for heart failure patients.
The round was led by 415 CAPITAL, a venture capital firm specializing in medical technology, with additional strategic investors.
Awarded €10M in grants and equity investment to accelerate clinical development of the V-sling system.